0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

1
INFLUENTIAL PUBLICATIONS   |    
Bibliography: Schizophrenia
FOCUS 2012;10:186-188. doi:10.1176/appi.focus.10.2.186

Abstract

This section contains a compilation of recent publications that have shaped the thinking in the field as well as classic works that remain important to the subject reviewed in this issue. This bibliography has been compiled by experts in the field and members of the editorial and advisory boards. Entries are listed chronologically and within years by first author. Articles from the bibliography that are reprinted in this issue are in bold type.

Abstract Teaser
Figures in this Article

Kishimoto  T;  Agarwal  V;  Kishi  T;  Leucht  S;  Kane  JM;  Correll  CU:  Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics.  Mol Psychiatry 2011; doi: 10.1038/mp.2011.143 [Epub ahead of print]
 
Ventura  J;  Subotnik  KL;  Guzik  LH;  Hellemann  GS;  Gitlin  MJ;  Wood  RC;  Nuechterlein  KH:  Remission and recovery during the first outpatient year of the early course of schizophrenia.  Schizophr Res 2011; 132:18–23
[PubMed]
[CrossRef]
 
Ripke  S;  Sanders  AR;  Kendler  KS;  Levinson  DF;  Sklar  P;  Gejman  PV  et al: Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium:  Genome-wide association study identifies five new schizophrenia loci.  Nat Genet 2011; 43:969–976
[PubMed]
[CrossRef]
 
Javitt  DC;  Schoepp  D;  Kalivas  PW;  Volkow  ND;  Zarate  C;  Merchant  K;  Bear  MF;  Umbricht  D;  Hajos  M;  Potter  WZ;  Lee  CM.  Translating glutamate: from pathophysiology to treatment.  Sci Transl Med . 2011 Sep 28;3(102):102mr2.
[CrossRef]
 
Lieberman JA, Stroup TS: The NIMH-CATIE Schizophrenia Study: what did we learn? Am J Psychiatry 2011; 168:770–775
[PubMed]
[CrossRef]
 
Belgamwar  RB;  El-Sayeh  HG:  Aripiprazole versus placebo for schizophrenia.  Cochrane Database Syst Rev 2011; (8):CD006622
 
Daumit  GL;  Dalcin  AT;  Jerome  GJ;  Young  DR;  Charleston  J;  Crum  RM;  Anthony  C;  Hayes  JH;  McCarron  PB;  Khaykin  E;  Appel  LJ:  A behavioral weight-loss intervention for persons with serious mental illness in psychiatric rehabilitation centers.  Int J Obes (Lond) 2011; 35:1114–1123
[PubMed]
[CrossRef]
 
McFarland BH, Collins JC: Medicaid cutbacks and state psychiatric hospitalization of patients with schizophrenia.  Psychiatr Serv 2011; 62:871–877
[PubMed]
[CrossRef]
 
Foley  DL;  Morley  KI:  Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis.  Arch Gen Psychiatry 2011; 68:609–616
[PubMed]
[CrossRef]
 
Wykes  T;  Huddy  V;  Cellard  C;  McGurk  SR;  Czobor  P:  A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes.  Am J Psychiatry 2011; 168:472–485
[PubMed]
[CrossRef]
 
Leucht  C;  Heres  S;  Kane  JM;  Kissling  W;  Davis  JM;  Leucht  S:  Oral versus depot antipsychotic drugs for schizophrenia—a critical systematic review and meta-analysis of randomised long-term trials.  Schizophr Res 2011; 127:83–92
[PubMed]
[CrossRef]
 
Subotnik KL, Nuechterlein KH, Ventura J, Gitlin MJ, Marder S, Mintz J, Hellemann GS, Thornton LA, Singh IR: Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia.  Am J Psychiatry 2011; 168:286–292
[PubMed]
[CrossRef]
 
Strom  BL;  Eng  SM;  Faich  G;  Reynolds  RF;  D’Agostino  RB;  Ruskin  J;  Kane  JM:  Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).  Am J Psychiatry 2011; 168:193–201
[PubMed]
[CrossRef]
 
Tranulis  C;  Goff  D;  Henderson  DC;  Freudenreich  O:  Becoming adherent to antipsychotics: a qualitative study of treatment-experienced schizophrenia patients.  Psychiatr Serv 2011; 62:888–892
[PubMed]
[CrossRef]
 
Beck  EM;  Cavelti  M;  Kvrgic  S;  Kleim  B;  Vauth  R:  Are we addressing the ‘right stuff’ to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication.  Schizophr Res 2011; 132:42–49
[PubMed]
[CrossRef]
 
Rosenheck  RA;  Krystal  JH;  Lew  R;  Barnett  PG;  Fiore  L;  Valley  D;  Thwin  SS;  Vertrees  JE;  Liang  MH; CSP555 Research Group:  Long-acting risperidone and oral antipsychotics in unstable schizophrenia.  N Engl J Med 2011; 364:842–851
[PubMed]
[CrossRef]
 
Farooq  S;  Nazar  Z;  Irfan  M;  Akhter  J;  Gul  E;  Irfan  U;  Naeem  F:  Schizophrenia medication adherence in a resource-poor setting: randomised controlled trial of supervised treatment in out-patients for schizophrenia (STOPS).  Br J Psychiatry 2011; 199:467–472
[PubMed]
[CrossRef]
 
Green  MF;  Schooler  NR;  Kern  RS  et al:  Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia.  Am J Psychiatry 2011; 168:400–407
[PubMed]
[CrossRef]
 
Dickerson FB, Lehman AF: Evidence-based psychotherapy for schizophrenia: 2011 update.  J Nerv Ment Dis 2011; 199:520–526
[PubMed]
[CrossRef]
 
Insel  TR:  Rethinking schizophrenia.  Nature 2010; 468:187–193
[PubMed]
[CrossRef]
 
Rummel-Kluge  C;  Komossa  K;  Schwarz  S;  Hunger  H;  Schmid  F;  Lobos  CA;  Kissling  W;  Davis  JM;  Leucht  S:  Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.  Schizophr Res 2010; 123:225–233
[PubMed]
[CrossRef]
 
Ballon  JS;  Lieberman  JA:  Advances in the management of treatment- resistant schizophrenia.  Focus 2010; 8:475–487
 
Foti  DJ;  Kotov  R;  Guey  LT;  Bromet  EJ:  Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization.  Am J Psychiatry 2010; 167:987–993
[PubMed]
[CrossRef]
 
Brown  AS;  Derkits  EJ:  Prenatal infection and schizophrenia: a review of epidemiologic and translational studies.  Am J Psychiatry 2010; 167:261–280
[PubMed]
[CrossRef]
 
Kane  JM;  Detke  HC;  Naber  D;  Sethuraman  G;  Lin  DY;  Bergstrom  RF;  McDonnell  D:  Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.  Am J Psychiatry 2010; 167:181–189
[PubMed]
[CrossRef]
 
Amminger  GP;  Schäfer  MR;  Papageorgiou  K;  Klier  CM;  Cotton  SM;  Harrigan  SM;  Mackinnon  A;  McGorry  PD;  Berger  GE:  Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.  Arch Gen Psychiatry 2010; 67:146–154
[PubMed]
[CrossRef]
 
Dixon  LB;  Dickerson  F;  Bellack  AS;  Bennett  M;  Dickinson  D;  Goldberg  RW;  Lehman  A;  Tenhula  WN;  Calmes  C;  Pasillas  RM;  Peer  J;  Kreyenbuhl  J; Schizophrenia Patient Outcomes Research Team (PORT):  The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements.  Schizophr Bull 2010; 36:48–70
[PubMed]
[CrossRef]
 
Kreyenbuhl  J;  Buchanan  RW;  Dickerson  FB;  Dixon  LB; Schizophrenia Patient Outcomes Research Team (PORT):  The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009.  Schizophr Bull 2010; 36:94–103
[PubMed]
[CrossRef]
 
Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W; Schizophrenia Patient Outcomes Research Team (PORT): The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.  Schizophr Bull 2010; 36:71–93
[PubMed]
[CrossRef]
 
Wang  CY;  Xiang  YT;  Cai  ZJ;  Weng  YZ;  Bo  QJ;  Zhao  JP;  Liu  TQ;  Wang  GH;  Weng  SM;  Zhang  HY;  Chen  DF;  Tang  WK;  Ungvari  GS; Risperidone Maintenance Treatment in Schizophrenia (RMTS) investigators:  Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial.  Am J Psychiatry 2010; 167:676–685
[PubMed]
[CrossRef]
 
Remington  G;  Foussias  G;  Agid  O:  Progress in defining optimal treatment outcome in schizophrenia.  CNS Drugs 2010; 24:9–20
[PubMed]
[CrossRef]
 
Hill  M;  Crumlish  N;  Whitty  P;  Clarke  M;  Browne  S;  Kamali  M;  Kinsella  A;  Waddington  JL;  Larkin  C;  O’Callaghan  E:  Nonadherence to medication four years after a first episode of psychosis and associated risk factors.  Psychiatr Serv 2010; 61:189–192
[PubMed]
[CrossRef]
 
Gaebel  W;  Riesbeck  M;  von Wilmsdorff  M;  Burns  T;  Derks  EM;  Kahn  RS;  Rössler  W;  Fleischhacker  WW; EUFEST Study Group:  Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST).  Eur Neuropsychopharmacol 2010; 20:310–316
[PubMed]
[CrossRef]
 
Velligan  D;  Sajatovic  M;  Valenstein  M;  Riley  WT;  Safren  S;  Lewis-Fernandez  R;  Weiden  P;  Ogedegbe  G;  Jamison  J:  Methodological challenges in psychiatric treatment adherence research.  Clin Schizophr Relat Psychoses 2010; 4:74–91
[PubMed]
[CrossRef]
 
Tiihonen  J;  Lönnqvist  J;  Wahlbeck  K;  Klaukka  T;  Niskanen  L;  Tanskanen  A;  Haukka  J:  11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).  Lancet 2009; 374:620–627
[PubMed]
[CrossRef]
 
Leucht  S;  Kissling  W;  Davis  JM:  Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med 2009; 39:1591–1602
[PubMed]
[CrossRef]
 
Need  AC;  Ge  D;  Weale  ME;  Maia  J;  Feng  S;  Heinzen  EL;  Shianna  KV;  Yoon  W;  Kasperaviciūte  D;  Gennarelli  M;  Strittmatter  WJ;  Bonvicini  C;  Rossi  G;  Jayathilake  K;  Cola  PA;  McEvoy  JP;  Keefe  RS;  Fisher  EM;  St Jean  PL;  Giegling  I;  Hartmann  AM;  Möller  HJ;  Ruppert  A;  Fraser  G;  Crombie  C;  Middleton  LT;  St Clair  D;  Roses  AD;  Muglia  P;  Francks  C;  Rujescu  D;  Meltzer  HY;  Goldstein  DB:  A genome-wide investigation of SNPs and CNVs in schizophrenia.  PLoS Genet 2009; 5:e1000373[open access] doi:10.1371/journal.pgen.1000373
[PubMed]
[CrossRef]
 
Leucht  S;  Komossa  K;  Rummel-Kluge  C;  Corves  C;  Hunger  H;  Schmid  F;  Asenjo Lobos  C;  Schwarz  S;  Davis  JM:  A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia.  Am J Psychiatry 2009; 166:152–163
[PubMed]
[CrossRef]
 
Staring  AB;  Mulder  CL;  Duivenvoorden  HJ;  De Haan  L;  Van der Gaag  M:  Fewer symptoms vs. more side-effects in schizophrenia? Opposing pathways between antipsychotic medication compliance and quality of life.  Schizophr Res 2009; 113:27–33
[PubMed]
[CrossRef]
 
Kern  RS;  Glynn  SM;  Horan  WP;  Marder  SR:  Psychosocial treatments to promote functional recovery in schizophrenia.  Schizophr Bull 2009; 35:347–361
[PubMed]
[CrossRef]
 
Kraemer  HC;  Glick  ID;  Klein  DF:  Clinical trials design lessons from the CATIE study.  Am J Psychiatry 2009; 166:1222–1228
[PubMed]
[CrossRef]
 
Buckley  PF;  Foster  A;  Miller  B:  Schizophrenia host vulnerability and risk of metabolic disturbances during treatment with antipsychotics.  Focus 2008; 6:172–179
 
Khazaal  Y;  Fresard  E;  Rabia  S;  Chatton  A;  Rothen  S;  Pomini  V;  Grasset  F;  Borgeat  F;  Zullino  D:  Cognitive behavioural therapy for weight gain associated with antipsychotic drugs.  Schizophr Res 2007; 91:169–177
[PubMed]
[CrossRef]
 
Velligan  DI;  Diamond  PM;  Mintz  J;  Maples  N;  Li  X;  Zeber  J;  Ereshefsky  L;  Lam  YW;  Castillo  D;  Miller  AL:  The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia.  Schizophr Bull 2008; 34:483–493
[PubMed]
[CrossRef]
 
Moore  TA;  Buchanan  RW;  Buckley  PF;  Chiles  JA;  Conley  RR;  Crismon  ML;  Essock  SM;  Finnerty  M;  Marder  SR;  Miller  DD;  McEvoy  JP;  Robinson  DG;  Schooler  NR;  Shon  SP;  Stroup  TS;  Miller  AL:  The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.  J Clin Psychiatry 2007; 68:1751–1762
[PubMed]
[CrossRef]
 
Saha  S;  Chant  D;  McGrath  J:  A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007; 64:1123–1131
[PubMed]
[CrossRef]
 
Moore  TH;  Zammit  S;  Lingford-Hughes  A;  Barnes  TR;  Jones  PB;  Burke  M;  Lewis  G:  Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.  Lancet 2007; 370:319–328
[PubMed]
[CrossRef]
 
Pompili  M;  Amador  XF;  Girardi  P;  Harkavy-Friedman  J;  Harrow  M;  Kaplan  K;  Krausz  M;  Lester  D;  Meltzer  HY;  Modestin  J;  Montross  LP;  Mortensen  PB;  Munk-Jørgensen  P;  Nielsen  J;  Nordentoft  M;  Saarinen  PI;  Zisook  S;  Wilson  ST;  Tatarelli  R:  Suicide risk in schizophrenia: learning from the past to change the future.  Ann Gen Psychiatry 2007; 6:10
[PubMed]
[CrossRef]
 
Miller  BJ;  Paschall  CB  3rd;  Svendsen  DP:  Mortality and medical comorbidity among patients with serious mental illness.  Psychiatr Serv 2006; 57:1482–1487
[PubMed]
[CrossRef]
 
Lieberman  JA;  Stroup  TS;  McEvoy  JP;  Swartz  MS;  Rosenheck  RA;  Perkins  DO;  Keefe  RS;  Davis  SM;  Davis  CE;  Lebowitz  BD;  Severe  J;  Hsiao  JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators:  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.  N Engl J Med 2005; 353:1209–1223
[PubMed]
[CrossRef]
 
McEvoy  JP;  Meyer  JM;  Goff  DC;  Nasrallah  HA;  Davis  SM;  Sullivan  L;  Meltzer  HY;  Hsiao  J;  Scott Stroup  T;  Lieberman  JA:  Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.  Schizophr Res 2005; 80:19–32
[PubMed]
[CrossRef]
 
Meltzer  HY;  Alphs  L;  Green  AI;  Altamura  AC;  Anand  R;  Bertoldi  A;  Bourgeois  M;  Chouinard  G;  Islam  MZ;  Kane  J;  Krishnan  R;  Lindenmayer  JP;  Potkin  S; International Suicide Prevention Trial Study Group:  Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).  Arch Gen Psychiatry 2003; 60:82–91
[PubMed]
[CrossRef]
 
References Container
+

References

Kishimoto  T;  Agarwal  V;  Kishi  T;  Leucht  S;  Kane  JM;  Correll  CU:  Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics.  Mol Psychiatry 2011; doi: 10.1038/mp.2011.143 [Epub ahead of print]
 
Ventura  J;  Subotnik  KL;  Guzik  LH;  Hellemann  GS;  Gitlin  MJ;  Wood  RC;  Nuechterlein  KH:  Remission and recovery during the first outpatient year of the early course of schizophrenia.  Schizophr Res 2011; 132:18–23
[PubMed]
[CrossRef]
 
Ripke  S;  Sanders  AR;  Kendler  KS;  Levinson  DF;  Sklar  P;  Gejman  PV  et al: Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium:  Genome-wide association study identifies five new schizophrenia loci.  Nat Genet 2011; 43:969–976
[PubMed]
[CrossRef]
 
Javitt  DC;  Schoepp  D;  Kalivas  PW;  Volkow  ND;  Zarate  C;  Merchant  K;  Bear  MF;  Umbricht  D;  Hajos  M;  Potter  WZ;  Lee  CM.  Translating glutamate: from pathophysiology to treatment.  Sci Transl Med . 2011 Sep 28;3(102):102mr2.
[CrossRef]
 
Lieberman JA, Stroup TS: The NIMH-CATIE Schizophrenia Study: what did we learn? Am J Psychiatry 2011; 168:770–775
[PubMed]
[CrossRef]
 
Belgamwar  RB;  El-Sayeh  HG:  Aripiprazole versus placebo for schizophrenia.  Cochrane Database Syst Rev 2011; (8):CD006622
 
Daumit  GL;  Dalcin  AT;  Jerome  GJ;  Young  DR;  Charleston  J;  Crum  RM;  Anthony  C;  Hayes  JH;  McCarron  PB;  Khaykin  E;  Appel  LJ:  A behavioral weight-loss intervention for persons with serious mental illness in psychiatric rehabilitation centers.  Int J Obes (Lond) 2011; 35:1114–1123
[PubMed]
[CrossRef]
 
McFarland BH, Collins JC: Medicaid cutbacks and state psychiatric hospitalization of patients with schizophrenia.  Psychiatr Serv 2011; 62:871–877
[PubMed]
[CrossRef]
 
Foley  DL;  Morley  KI:  Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis.  Arch Gen Psychiatry 2011; 68:609–616
[PubMed]
[CrossRef]
 
Wykes  T;  Huddy  V;  Cellard  C;  McGurk  SR;  Czobor  P:  A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes.  Am J Psychiatry 2011; 168:472–485
[PubMed]
[CrossRef]
 
Leucht  C;  Heres  S;  Kane  JM;  Kissling  W;  Davis  JM;  Leucht  S:  Oral versus depot antipsychotic drugs for schizophrenia—a critical systematic review and meta-analysis of randomised long-term trials.  Schizophr Res 2011; 127:83–92
[PubMed]
[CrossRef]
 
Subotnik KL, Nuechterlein KH, Ventura J, Gitlin MJ, Marder S, Mintz J, Hellemann GS, Thornton LA, Singh IR: Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia.  Am J Psychiatry 2011; 168:286–292
[PubMed]
[CrossRef]
 
Strom  BL;  Eng  SM;  Faich  G;  Reynolds  RF;  D’Agostino  RB;  Ruskin  J;  Kane  JM:  Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).  Am J Psychiatry 2011; 168:193–201
[PubMed]
[CrossRef]
 
Tranulis  C;  Goff  D;  Henderson  DC;  Freudenreich  O:  Becoming adherent to antipsychotics: a qualitative study of treatment-experienced schizophrenia patients.  Psychiatr Serv 2011; 62:888–892
[PubMed]
[CrossRef]
 
Beck  EM;  Cavelti  M;  Kvrgic  S;  Kleim  B;  Vauth  R:  Are we addressing the ‘right stuff’ to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication.  Schizophr Res 2011; 132:42–49
[PubMed]
[CrossRef]
 
Rosenheck  RA;  Krystal  JH;  Lew  R;  Barnett  PG;  Fiore  L;  Valley  D;  Thwin  SS;  Vertrees  JE;  Liang  MH; CSP555 Research Group:  Long-acting risperidone and oral antipsychotics in unstable schizophrenia.  N Engl J Med 2011; 364:842–851
[PubMed]
[CrossRef]
 
Farooq  S;  Nazar  Z;  Irfan  M;  Akhter  J;  Gul  E;  Irfan  U;  Naeem  F:  Schizophrenia medication adherence in a resource-poor setting: randomised controlled trial of supervised treatment in out-patients for schizophrenia (STOPS).  Br J Psychiatry 2011; 199:467–472
[PubMed]
[CrossRef]
 
Green  MF;  Schooler  NR;  Kern  RS  et al:  Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia.  Am J Psychiatry 2011; 168:400–407
[PubMed]
[CrossRef]
 
Dickerson FB, Lehman AF: Evidence-based psychotherapy for schizophrenia: 2011 update.  J Nerv Ment Dis 2011; 199:520–526
[PubMed]
[CrossRef]
 
Insel  TR:  Rethinking schizophrenia.  Nature 2010; 468:187–193
[PubMed]
[CrossRef]
 
Rummel-Kluge  C;  Komossa  K;  Schwarz  S;  Hunger  H;  Schmid  F;  Lobos  CA;  Kissling  W;  Davis  JM;  Leucht  S:  Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.  Schizophr Res 2010; 123:225–233
[PubMed]
[CrossRef]
 
Ballon  JS;  Lieberman  JA:  Advances in the management of treatment- resistant schizophrenia.  Focus 2010; 8:475–487
 
Foti  DJ;  Kotov  R;  Guey  LT;  Bromet  EJ:  Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization.  Am J Psychiatry 2010; 167:987–993
[PubMed]
[CrossRef]
 
Brown  AS;  Derkits  EJ:  Prenatal infection and schizophrenia: a review of epidemiologic and translational studies.  Am J Psychiatry 2010; 167:261–280
[PubMed]
[CrossRef]
 
Kane  JM;  Detke  HC;  Naber  D;  Sethuraman  G;  Lin  DY;  Bergstrom  RF;  McDonnell  D:  Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.  Am J Psychiatry 2010; 167:181–189
[PubMed]
[CrossRef]
 
Amminger  GP;  Schäfer  MR;  Papageorgiou  K;  Klier  CM;  Cotton  SM;  Harrigan  SM;  Mackinnon  A;  McGorry  PD;  Berger  GE:  Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.  Arch Gen Psychiatry 2010; 67:146–154
[PubMed]
[CrossRef]
 
Dixon  LB;  Dickerson  F;  Bellack  AS;  Bennett  M;  Dickinson  D;  Goldberg  RW;  Lehman  A;  Tenhula  WN;  Calmes  C;  Pasillas  RM;  Peer  J;  Kreyenbuhl  J; Schizophrenia Patient Outcomes Research Team (PORT):  The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements.  Schizophr Bull 2010; 36:48–70
[PubMed]
[CrossRef]
 
Kreyenbuhl  J;  Buchanan  RW;  Dickerson  FB;  Dixon  LB; Schizophrenia Patient Outcomes Research Team (PORT):  The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009.  Schizophr Bull 2010; 36:94–103
[PubMed]
[CrossRef]
 
Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W; Schizophrenia Patient Outcomes Research Team (PORT): The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.  Schizophr Bull 2010; 36:71–93
[PubMed]
[CrossRef]
 
Wang  CY;  Xiang  YT;  Cai  ZJ;  Weng  YZ;  Bo  QJ;  Zhao  JP;  Liu  TQ;  Wang  GH;  Weng  SM;  Zhang  HY;  Chen  DF;  Tang  WK;  Ungvari  GS; Risperidone Maintenance Treatment in Schizophrenia (RMTS) investigators:  Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial.  Am J Psychiatry 2010; 167:676–685
[PubMed]
[CrossRef]
 
Remington  G;  Foussias  G;  Agid  O:  Progress in defining optimal treatment outcome in schizophrenia.  CNS Drugs 2010; 24:9–20
[PubMed]
[CrossRef]
 
Hill  M;  Crumlish  N;  Whitty  P;  Clarke  M;  Browne  S;  Kamali  M;  Kinsella  A;  Waddington  JL;  Larkin  C;  O’Callaghan  E:  Nonadherence to medication four years after a first episode of psychosis and associated risk factors.  Psychiatr Serv 2010; 61:189–192
[PubMed]
[CrossRef]
 
Gaebel  W;  Riesbeck  M;  von Wilmsdorff  M;  Burns  T;  Derks  EM;  Kahn  RS;  Rössler  W;  Fleischhacker  WW; EUFEST Study Group:  Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST).  Eur Neuropsychopharmacol 2010; 20:310–316
[PubMed]
[CrossRef]
 
Velligan  D;  Sajatovic  M;  Valenstein  M;  Riley  WT;  Safren  S;  Lewis-Fernandez  R;  Weiden  P;  Ogedegbe  G;  Jamison  J:  Methodological challenges in psychiatric treatment adherence research.  Clin Schizophr Relat Psychoses 2010; 4:74–91
[PubMed]
[CrossRef]
 
Tiihonen  J;  Lönnqvist  J;  Wahlbeck  K;  Klaukka  T;  Niskanen  L;  Tanskanen  A;  Haukka  J:  11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).  Lancet 2009; 374:620–627
[PubMed]
[CrossRef]
 
Leucht  S;  Kissling  W;  Davis  JM:  Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med 2009; 39:1591–1602
[PubMed]
[CrossRef]
 
Need  AC;  Ge  D;  Weale  ME;  Maia  J;  Feng  S;  Heinzen  EL;  Shianna  KV;  Yoon  W;  Kasperaviciūte  D;  Gennarelli  M;  Strittmatter  WJ;  Bonvicini  C;  Rossi  G;  Jayathilake  K;  Cola  PA;  McEvoy  JP;  Keefe  RS;  Fisher  EM;  St Jean  PL;  Giegling  I;  Hartmann  AM;  Möller  HJ;  Ruppert  A;  Fraser  G;  Crombie  C;  Middleton  LT;  St Clair  D;  Roses  AD;  Muglia  P;  Francks  C;  Rujescu  D;  Meltzer  HY;  Goldstein  DB:  A genome-wide investigation of SNPs and CNVs in schizophrenia.  PLoS Genet 2009; 5:e1000373[open access] doi:10.1371/journal.pgen.1000373
[PubMed]
[CrossRef]
 
Leucht  S;  Komossa  K;  Rummel-Kluge  C;  Corves  C;  Hunger  H;  Schmid  F;  Asenjo Lobos  C;  Schwarz  S;  Davis  JM:  A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia.  Am J Psychiatry 2009; 166:152–163
[PubMed]
[CrossRef]
 
Staring  AB;  Mulder  CL;  Duivenvoorden  HJ;  De Haan  L;  Van der Gaag  M:  Fewer symptoms vs. more side-effects in schizophrenia? Opposing pathways between antipsychotic medication compliance and quality of life.  Schizophr Res 2009; 113:27–33
[PubMed]
[CrossRef]
 
Kern  RS;  Glynn  SM;  Horan  WP;  Marder  SR:  Psychosocial treatments to promote functional recovery in schizophrenia.  Schizophr Bull 2009; 35:347–361
[PubMed]
[CrossRef]
 
Kraemer  HC;  Glick  ID;  Klein  DF:  Clinical trials design lessons from the CATIE study.  Am J Psychiatry 2009; 166:1222–1228
[PubMed]
[CrossRef]
 
Buckley  PF;  Foster  A;  Miller  B:  Schizophrenia host vulnerability and risk of metabolic disturbances during treatment with antipsychotics.  Focus 2008; 6:172–179
 
Khazaal  Y;  Fresard  E;  Rabia  S;  Chatton  A;  Rothen  S;  Pomini  V;  Grasset  F;  Borgeat  F;  Zullino  D:  Cognitive behavioural therapy for weight gain associated with antipsychotic drugs.  Schizophr Res 2007; 91:169–177
[PubMed]
[CrossRef]
 
Velligan  DI;  Diamond  PM;  Mintz  J;  Maples  N;  Li  X;  Zeber  J;  Ereshefsky  L;  Lam  YW;  Castillo  D;  Miller  AL:  The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia.  Schizophr Bull 2008; 34:483–493
[PubMed]
[CrossRef]
 
Moore  TA;  Buchanan  RW;  Buckley  PF;  Chiles  JA;  Conley  RR;  Crismon  ML;  Essock  SM;  Finnerty  M;  Marder  SR;  Miller  DD;  McEvoy  JP;  Robinson  DG;  Schooler  NR;  Shon  SP;  Stroup  TS;  Miller  AL:  The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.  J Clin Psychiatry 2007; 68:1751–1762
[PubMed]
[CrossRef]
 
Saha  S;  Chant  D;  McGrath  J:  A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007; 64:1123–1131
[PubMed]
[CrossRef]
 
Moore  TH;  Zammit  S;  Lingford-Hughes  A;  Barnes  TR;  Jones  PB;  Burke  M;  Lewis  G:  Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.  Lancet 2007; 370:319–328
[PubMed]
[CrossRef]
 
Pompili  M;  Amador  XF;  Girardi  P;  Harkavy-Friedman  J;  Harrow  M;  Kaplan  K;  Krausz  M;  Lester  D;  Meltzer  HY;  Modestin  J;  Montross  LP;  Mortensen  PB;  Munk-Jørgensen  P;  Nielsen  J;  Nordentoft  M;  Saarinen  PI;  Zisook  S;  Wilson  ST;  Tatarelli  R:  Suicide risk in schizophrenia: learning from the past to change the future.  Ann Gen Psychiatry 2007; 6:10
[PubMed]
[CrossRef]
 
Miller  BJ;  Paschall  CB  3rd;  Svendsen  DP:  Mortality and medical comorbidity among patients with serious mental illness.  Psychiatr Serv 2006; 57:1482–1487
[PubMed]
[CrossRef]
 
Lieberman  JA;  Stroup  TS;  McEvoy  JP;  Swartz  MS;  Rosenheck  RA;  Perkins  DO;  Keefe  RS;  Davis  SM;  Davis  CE;  Lebowitz  BD;  Severe  J;  Hsiao  JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators:  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.  N Engl J Med 2005; 353:1209–1223
[PubMed]
[CrossRef]
 
McEvoy  JP;  Meyer  JM;  Goff  DC;  Nasrallah  HA;  Davis  SM;  Sullivan  L;  Meltzer  HY;  Hsiao  J;  Scott Stroup  T;  Lieberman  JA:  Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.  Schizophr Res 2005; 80:19–32
[PubMed]
[CrossRef]
 
Meltzer  HY;  Alphs  L;  Green  AI;  Altamura  AC;  Anand  R;  Bertoldi  A;  Bourgeois  M;  Chouinard  G;  Islam  MZ;  Kane  J;  Krishnan  R;  Lindenmayer  JP;  Potkin  S; International Suicide Prevention Trial Study Group:  Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).  Arch Gen Psychiatry 2003; 60:82–91
[PubMed]
[CrossRef]
 
References Container
+
+

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content
Articles
Books
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 1.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 2.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 9.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 6.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 10.  >
Topic Collections
Psychiatric News
Read more at Psychiatric News >>
APA Guidelines
PubMed Articles